XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Collaborative Arrangements (Tables)
 6 Months Ended
Jun. 30, 2022
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2022202120222021
Alliance revenue - Lynparza$275 $248 $541 $475 
Alliance revenue - Koselugo24 8 33 14 
Total alliance revenue$299 $256 $574 $489 
Cost of sales (1)
62 42 361 84 
Selling, general and administrative46 43 90 83 
Research and development25 31 51 60 
($ in millions)June 30, 2022December 31, 2021
Receivables from AstraZeneca included in Other current assets
$300 $271 
Payables to AstraZeneca included in Trade accounts payable and Accrued and other current liabilities (2)
12 415 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
600 — 
(1) Represents amortization of capitalized milestone payments. Amount in the first six months of 2022 includes $250 million of cumulative amortization catch-up expense as noted above.
(2) Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2022202120222021
Alliance revenue - Lenvima$231 $181 $459 $310 
Cost of sales (1)
53 47 106 94 
Selling, general and administrative42 31 73 54 
Research and development47 57 104 121 
($ in millions)June 30, 2022December 31, 2021
Receivables from Eisai included in Other current assets
$247 $200 
Payables to Eisai included in Accrued and other current liabilities (2)
25 625 
(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2022202120222021
Alliance revenue - Adempas/Verquvo$98 $74 $170 $149 
Net sales of Adempas recorded by Merck63 74 124 129 
Net sales of Verquvo recorded by Merck6 1 9 1 
Total sales$167 $149 $303 $279 
Cost of sales (1)
54 67 103 275 
Selling, general and administrative42 34 65 51 
Research and development17 13 34 20 
($ in millions)June 30, 2022December 31, 2021
Receivables from Bayer included in Other current assets
$144 $114 
Payables to Bayer included in Accrued and other current liabilities (2)
74 472 
(1) Includes amortization of intangible assets. Amount in the first six months of 2021 includes $153 million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
(2) Amount as of December 31, 2021 includes accrued milestone payment.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2022202120222021
Lagevrio sales
$1,177 $— $4,424 $— 
Cost of sales (1)
622 6 2,338 52 
Selling, general and administrative30 4 65 7 
Research and development 15 68 21 110 
($ in millions)June 30, 2022December 31, 2021
Payables to Ridgeback included in Accrued and other current liabilities (2)
$683 $283 
(1) Includes royalty expense and amortization of capitalized milestone payments.
(2) Includes accrued royalty and milestone payments.